ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer—A Multicenter Study
There are no conflicts of interests.
- 2.Coleman R, Enserro D, Spirtos N, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36 (suppl; abstr 5501).CrossRefGoogle Scholar
© Society of Surgical Oncology 2018